Abstract
We report the case of a female patient with chronic active Epstein–Barr virus infection (CAEBV) accompanied by hemophagocytic syndrome (HPS). On admission, she presented with severe liver dysfunction and disseminated intravascular coagulation with elevation of serum IL-6, TNF-α, and IFN-γ levels. Plasma exchange (PE) followed by immunochemotherapy with prednisolone, cyclosporine A, and VP16 was performed. PE decreased serum cytokine levels dramatically and improved liver function. Following immunochemotherapy, CAEBV became inactive. Four months after discharge, however, CAEBV relapsed with HPS, and serum cytokine levels were extremely elevated again. There was no response to immunochemotherapy, and the patient died 1 day after admission. We examined the cytokines in five additional untreated-CAEBV patients and determined that they were elevated above the normal level in all patients. These results suggest that inflammatory cytokines may have roles in the development of CAEBV, and that their depletion can be an effective treatment for this disease.
This is a preview of subscription content, log in via an institution to check access.
References
Kawa K. Epstein–Barr virus-associated diseases in humans. Int J Hematol. 2000;71:108–17.
Quintanilla-Martinez L, Kimura H, Jaffe ES. EBV-positive T-cell lymphoproliferative disorders of childhood. In: Jaffe E, Harris N, Stein H, Vardiman JW, editors. World Health Organization classification of tumors pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. p. 278–80.
Kimura H. Pathogenesis of chronic active Epstein–Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? Rev Med Virol. 2006;16:251–61.
Lay JD, Tsao CJ, Chen JY, et al. Upregulation of tumor necrosis factor-alpha gene by Epstein–Barr virus and activation of macrophages in Epstein–Barr virus-infected T cells in the pathogenesis of hemophagocytic syndrome. J Clin Invest. 1997;100:1969–79.
Sato S, Kawashima H, Oshiro H, et al. Virological and immunological characteristics of a 19-year-old Japanese female with fatal outcome with Epstein–Barr virus-associated hemophagocytic syndrome. J Clin Virol. 2004;31:235–8.
Cohen JI, Jaffe ES, Dale JK, et al. Characterization and treatment of chronic active Epstein–Barr virus disease: a 28-year experience in the United States. Blood. 2011;117:5835–49.
Imadome K, Shimizu N, Arai A, et al. Coexpression of CD40 and CD40 ligand in Epstein–Barr virus-infected T and NK cells and their role in cell survival. J Infect Dis. 2005;192:1340–8.
Okano M, Kawa K, Kimura H, et al. Proposed guidelines for diagnosing chronic active Epstein–Barr virus infection. Am J Hematol. 2005;80:64–9.
Henter JI, Horne A, Aricó M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–31.
Koyama M, Takeshita Y, Sakata A, et al. Cytotoxic chemotherapy successfully induces durable complete remission in 2 patients with mosquito allergy resulting from Epstein–Barr virus-associated T-/natural killer cell lymphoproliferative disease. Int J Hematol. 2005;82:437–40.
Imadome K, Yajima M, Arai A, et al. Novel mouse xenograft models reveal a critical role of CD4 T cells in the proliferation of EBV-infected T and NK cells. PLoS Pathog. 2011;7:e1002326.
Ogawa J, Koike R, Sugihara T, et al. An autopsied case of chronic active Epstein–Barr virus infection complicated in systemic lupus erythematosus and antiphospholipid antibody syndrome. Nihon Rinsho Meneki Gakkai Kaishi. 2002;25:458–65.
Young KH, Zhang D, Malik JT, et al. Fulminant EBV-driven CD8 T-cell lymphoproliferative disorder following primary acute EBV infection: a unique spectrum of T-cell malignancy. Int J Clin Exp Pathol. 2008;1:185–97.
Tokuhira M, Hanzawa K, Watanabe R, et al. Co-existence of acute myeloid leukemia with multilineage dysplasia and Epstein–Barr virus-associated T-cell lymphoproliferative disorder in a patient with rheumatoid arthritis: a case report. J Hematol Oncol. 2009;2:27.
Arai A, Imadome K, Watanabe Y, et al. Clinical features of adult-onset chronic active Epstein–Barr virus infection: a retrospective analysis. Int J Hematol. 2011;93:602–9.
Kimura H, Morita M, Yabuta Y, et al. Quantitative analysis of Epstein–Barr virus load by using a real-time PCR assay. J Clin Microbiol. 1999;37:132–6.
Roncella S, Cutrona G, Truini M, et al. Late Epstein–Barr virus infection of a hepatosplenic gamma delta T-cell lymphoma arising in a kidney transplant recipient. Haematologica. 2000;85:256–62.
Kanno H, Watabe D, Shimizu N, et al. Adhesion of Epstein–Barr virus-positive natural killer cell lines to cultured endothelial cells stimulated with inflammatory cytokines. Clin Exp Immunol. 2008;151:519–27.
Kawa K, Sawada A, Sato M, et al. Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection. Bone Marrow Transpl. 2011;46:77–83.
Henzan T, Nagafuji K, Tsukamoto H, et al. Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis. Am J Hematol. 2006;81:59–61.
Kikuchi H, Yamamoto T, Asako K, et al. Etanercept for the treatment of intractable hemophagocytic syndrome with systemic lupus erythematosus. Mod Rheumatol 2011;22:308–11.
Acknowledgments
This study was supported by a grant from Ministry of Health, Labor and Welfare of Japan (H24-Nanchi-046) and a grant from Ministry of Education, Culture, Sports, Science, and Technology of Japan (23591375). The ethics committee of Tokyo Medical and Dental University Hospital approved this study, and written informed consent was obtained from the patient.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Arai, A., Nogami, A., Imadome, KI. et al. Sequential monitoring of serum IL-6, TNF-α, and IFN-γ levels in a CAEBV patient treated by plasma exchange and immunochemotherapy. Int J Hematol 96, 669–673 (2012). https://doi.org/10.1007/s12185-012-1170-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-012-1170-2